Actimmune, Interferon Gamma-1b

Actimmune, Interferon Gamma-1b Newswire

Comprehensive Real-Time News Feed for Actimmune, Interferon Gamma-1b (generic).

Results 1 - 20 of 114 in Actimmune, Interferon Gamma-1b (generic)

  1. Horizon Pharma plc Announces Waiver of Financing Proceeds ConditionRead the original story w/Photo

    Thursday Apr 30 | Market Wire

    The tender offer is scheduled to expire at 12:01 a.m. on Thursday, May 7, 2015, unless further extended or earlier terminated. All other terms and conditions of the tender offer remain unchanged, including, without limitation, the "Minimum Condition" described in the Offer to Purchase.

    Comment?

  2. Horizon Pharma To Host First Quarter 2015 Conference Call And Webcast On May 8, 2015Read the original story

    Monday Apr 27 | BioSpace

    Horizon Pharma plc , a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, announced today that its first quarter 2015 financial results will be released on Friday, May 8, 2015. Following the announcement, Horizon's management will host a live conference call and webcast at 8 a.m. Eastern Time to review the Company's financial and operating results, discuss recent transactions and provide a general business update.

    Comment?

  3. Horizon Pharma Announces Pricing Of Private Offering Of Senior NotesRead the original story

    Monday Apr 27 | BioSpace

    Horizon Pharma plc , a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced that Horizon Pharma Financing Inc., its wholly-owned subsidiary , has priced its offering of $475 million aggregate principal amount of 6.625% senior notes due 2023. The note offering is expected to close on or about April 29, 2015.

    Comment?

  4. Horizon Pharma plc Announces Pricing of Private Offering of Senior NotesRead the original story w/Photo

    Friday Apr 24 | Market Wire

    The note offering is expected to close on or about April 29, 2015. The size of the offering was increased above the previously-announced size of $300 million aggregate principal amount of notes.

    Comment?

  5. Horizon Pharma Announces Proposed Private Offering Of Senior Notes...Read the original story

    Sunday Apr 19 | BioSpace

    Horizon Pharma plc , a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced that Horizon Pharma Financing Inc., its wholly-owned subsidiary , intends, subject to market and other considerations, to offer $300 million aggregate principal amount of senior notes due 2023, and that Horizon Pharma, Inc., the parent of the Issuer and a wholly-owned subsidiary of Horizon , intends to enter into a new term loan facility in an aggregate principal amount of $500 million.

    Comment?

  6. FDA News Roundup: Teva, AstraZeneca, Amgen, Medicines Company, And MoreRead the original story w/Photo

    Friday Apr 17 | Pharmaceutical Online

    Cabozantinib received fast-track designation as a second-line treatment for advanced renal cell carcinoma. The candidate inhibits the MET, VEGFRs, and RET tyrosine kinases, and is currently being investigated in the Phase 3 METEOR trial for patients who have been treated previously with another VEGF tyrosine kinase inhibitor.

    Comment?

  7. Horizon Pharma (HZNP) Stock Rises in After-Hours Trading Following Pricing of Secondary OfferingRead the original story w/Photo

    Thursday Apr 16 | TheStreet.com

    The Dublin, Ireland-based company expects to proceeds from the offering, which is expected to close April 21, to be approximately $413.1 million. Underwriters will have an additional 30 days to purchase up to 2,302,500 ordinary shares.

    Comment?

  8. Horizon Pharma (HZNP) Stock Rises in After-Hours Trading Following Pricing of Secondary OfferingRead the original story w/Photo

    Thursday Apr 16 | TheStreet.com

    Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

    Comment?

  9. Horizon Pharma (HZNP) Stock Falls in After-Hours Today Following Public Share Offering AnnouncementRead the original story w/Photo

    Monday Apr 13 | TheStreet.com

    Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

    Comment?

  10. Horizon Pharma Receives FDA Fast Track Designation For ACTIMMUNE In...Read the original story

    Thursday Apr 9 | BioSpace

    Horizon Pharma plc , a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced the U.S. Food and Drug Administration granted Fast Track designation for ACTIMMUNE in the treatment of Friedreich's ataxia , a degenerative neuro-muscular disorder. "We commend the FDA for granting Fast Track designation for ACTIMMUNE in Friedreich's ataxia to potentially help treat patients suffering from this debilitating disorder, for which there are no FDA approved treatments available," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc.

    Comment?

  11. Horizon Pharma plc Receives FDA Fast Track Designation for ACTIMMUNE(R) in theRead the original story w/Photo

    Friday Apr 10 | Pharmaceutical Processing

    Horizon Pharma plc, a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced the U.S. Food and Drug Administration granted Fast Track designation for ACTIMMUNE in the treatment of Friedreich's ataxia , a degenerative neuro-muscular disorder. "We commend the FDA for granting Fast Track designation for ACTIMMUNE in Friedreich's ataxia to potentially help treat patients suffering from this debilitating disorder, for which there are no FDA approved treatments available," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc.

    Comment?

  12. Early Edge: Galena Biopharma, Inc., Horizon Pharma PLC, and AstraZeneca PLCRead the original story

    Friday Apr 10 | SchaeffersResearch.com

    Among the equities making an early splash on the Street are drugmakers Galena Biopharma Inc , Horizon Pharma PLC , and AstraZeneca plc . GALE tumbled to a two-year low of $1.30 out of the gate -- and was last seen down 5.7% at $1.32.

    Comment?

  13. Horizon Pharma's Friedreich's Ataxia Drug Gets Fast-Track DesignationRead the original story w/Photo

    Friday Apr 10 | Wall Street Journal

    Horizon Pharma PLC said Friday that its experimental Friedreich's ataxia treatment has received fast-track designation from the U.S. Food and Drug Administration, a move that could speed approval.

    Comment?

  14. Stock Futures Pare Early Gains; GE, Chipotle, Netflix RisingRead the original story w/Photo

    Friday Apr 10 | Investor's Business Daily

    Dow futures were 41.3 points above fair market value. S&P 500 futures pared gains to 4.3 points.

    Comment?

  15. Horizon Pharma plc Receives FDA Fast Track Designation for...Read the original story w/Photo

    Friday Apr 10 | Market Wire

    "We commend the FDA for granting Fast Track designation for ACTIMMUNE in Friedreich's ataxia to potentially help treat patients suffering from this debilitating disorder, for which there are no FDA approved treatments available," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "We look forward to continuing our ongoing clinical development program as we evaluate ACTIMMUNE in this patient population."

    Comment?

  16. The Effect Of Hyperion Acquisition On Horizon's Upside PotentialRead the original story w/Photo

    Thursday Apr 9 | Seeking Alpha

    Horizon continues to execute its plan of driving top and bottom line growth through acquisitions. Last week, the company announced the acquisition of Hyperion for $1.1 billion, which is expected to be immediately accretive to earnings and to add $100 million to 2016 EBITDA.

    Comment?

  17. Horizon Pharma Names Group Vice President, Corporate CommunicationsRead the original story

    Wednesday Apr 8 | BioSpace

    Horizon Pharma plc , a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today named Geoffrey M. Curtis group vice president, corporate communications, reporting directly to Timothy P. Walbert, chairman, president and chief executive officer, effective immediately. Curtis will oversee corporate and product communications, media relations and internal communications activities.

    Comment?

  18. Horizon Pharma plc Names Geoffrey M. Curtis Group Vice President, Corporate CommunicationsRead the original story w/Photo

    Thursday Apr 9 | Market Wire

    Horizon Pharma plc , a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today named Geoffrey M. Curtis group vice president, corporate communications, reporting directly to Timothy P. Walbert, chairman, president and chief executive officer, effective immediately. Curtis will oversee corporate and product communications, media relations and internal communications activities.

    Comment?

  19. Horizon Pharma to buy Brisbane's Hyperion TherapeuticsRead the original story w/Photo

    Mar 31, 2015 | SFGate

    Horizon Pharma agreed to buy Brisbane's Hyperion Therapeutics for $1.1 billion to gain drugs to treat rare metabolic diseases, adding to this year's numerous pharmaceutical industry takeovers. Horizon will offer Hyperion holders $46 per share in cash, the companies said.

    Comment?

  20. Horizon Pharma buying Hyperion for about $1.1 billionRead the original story

    Mar 30, 2015 | Los Angeles Times

    Dublin-based Horizon Pharma said Monday that it would pay $46 a share for the Brisbane, Calif., company, marking a 5.6% premium to Hyperion's closing stock price Friday, before the deal was announced. The move adds the drugs Raviciti and Buphenyl to Horizon's offerings.

    Comment?